{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=46", "query": { "intervention": "Continuous Dose", "page": 46 }, "page_size": 10 }, "pagination": { "page": 46, "page_size": 10, "total_count": 5326, "total_pages": 533, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=47&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=45&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-08T18:39:12.494Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04478227", "title": "TPO-Mimetic Use in Children for Hematopoietic Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Bone Marrow Failure Disorders", "Aplastic Anemia", "Thrombocytopenia", "Refractory Cytopenia of Childhood", "Myelodysplastic Syndrome(MDS)" ], "interventions": [ { "name": "Romiplostim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anjali Sharathkumar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "0 Years to 21 Years" }, "enrollment_count": 15, "start_date": "2020-08-18", "completion_date": "2024-01-18", "has_results": false, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04478227" }, { "nct_id": "NCT00914940", "title": "Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "Total-Body Irradiation (TBI)", "type": "RADIATION" }, { "name": "Magnetic Affinity Cell Sorting", "type": "OTHER" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "T Cell-Depleted Hematopoietic Stem Cell Transplantation", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "PROCEDURE", "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "14 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "14 Years to 55 Years" }, "enrollment_count": 41, "start_date": "2009-12-17", "completion_date": "2020-05-26", "has_results": true, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 2, "location_summary": "New Haven, Connecticut • Seattle, Washington", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00914940" }, { "nct_id": "NCT04422210", "title": "A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2020-09-22", "completion_date": "2020-11-06", "has_results": true, "last_update_posted_date": "2021-11-08", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04422210" }, { "nct_id": "NCT02719613", "title": "Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2016-07-15", "completion_date": "2026-02-23", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 14, "location_summary": "Tucson, Arizona • Bakersfield, California • Fountain Valley, California + 11 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "West Hollywood", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02719613" }, { "nct_id": "NCT00671060", "title": "Misoprostol for Treatment of Fetal Death at 14-28 Weeks of Pregnancy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Intrauterine Fetal Demise" ], "interventions": [ { "name": "Misoprostol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynuity Health Projects", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 153, "start_date": "2008-10", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2013-05-08", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 4, "location_summary": "Palo Alto, California • Newark, Delaware • Chicago, Illinois + 1 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Chicago", "state": "Illinois" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671060" }, { "nct_id": "NCT02579382", "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "TDF", "type": "DRUG" }, { "name": "Vesatolimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 192, "start_date": "2015-11-10", "completion_date": "2019-05-03", "has_results": true, "last_update_posted_date": "2020-05-18", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 9, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT02579382" }, { "nct_id": "NCT01421524", "title": "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma", "Lymphoma, Large B-Cell, Diffuse", "Pleiotropic Pathway Modifier", "Glioblastoma", "Lymphoma", "Primary Central Nervous System Lymphoma" ], "interventions": [ { "name": "CC-122", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 271, "start_date": "2011-09-12", "completion_date": "2023-11-21", "has_results": false, "last_update_posted_date": "2023-12-12", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 17, "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01421524" }, { "nct_id": "NCT02074059", "title": "Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Distress Syndrome" ], "interventions": [ { "name": "Lucinactant for Inhalation", "type": "DRUG" }, { "name": "nCPAP alone", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Windtree Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "29 Weeks", "maximum_age": "34 Weeks", "sex": "ALL", "summary": "29 Weeks to 34 Weeks" }, "enrollment_count": 80, "start_date": "2014-02", "completion_date": "2015-11", "has_results": true, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 11, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02074059" }, { "nct_id": "NCT06841679", "title": "Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric or Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Utidelone Capsule", "type": "DRUG" }, { "name": "Fluoropyrimidine- and Platinum-containing Therapy", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "PD-1 inhibitor", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beijing Biostar Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 778, "start_date": "2025-08-28", "completion_date": "2030-09-01", "has_results": false, "last_update_posted_date": "2025-11-25", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 1, "location_summary": "Hialeah, Florida", "locations": [ { "city": "Hialeah", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06841679" }, { "nct_id": "NCT07167446", "title": "Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients", "Metastatic Colorectal Cancer (CRC)", "Peripheral Neuropathy Due to Chemotherapy" ], "interventions": [ { "name": "Cannabidiol (CBD)", "type": "DRUG" }, { "name": "oxaliplatin-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fox Chase Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-10-14", "completion_date": "2028-09-07", "has_results": false, "last_update_posted_date": "2026-10-29", "last_synced_at": "2026-11-08T18:39:12.494Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07167446" } ] }